NK-92
Acute Myeloid Leukemia With Multilineage Dysplasia
Explore 33 assets in Acute Myeloid Leukemia With Multilineage Dysplasia →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02727803CT.gov Personalized NK Cell Therapy in CBT | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia With Multilineage Dysplasia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| NK-92 (this asset) | M.D. Anderson Cancer Center | P2 | CCC · 53 |
| Cytarabine | National Cancer Institute (NCI) | P3 | BB |
| Etoposide | Institut de Recherches Internationales Servier | P2 | BB |
| Decitabine | National Cancer Institute (NCI) | P3 | BB |
| Ivosidenib | Institut de Recherches Internationales Servier | P3 | BB |
| Cyclophosphamide | City of Hope Medical Center | P3 | BB |
| Fludarabine | National Cancer Institute (NCI) | P3 | BB |
| Busulfanum | National Cancer Institute (NCI) | P3 | BB |
| Cyclosporin A | Case Comprehensive Cancer Center | P3 | BB |
+41 more in the Acute Myeloid Leukemia With Multilineage Dysplasia cohort
Other indications for NK-92
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Biphenotypic Leukemia | — | P2 | CCC · 53 |
| Chronic Myeloid Leukemia | — | P2 | CCC · 53 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. NK-92 in Acute Myeloid Leukemia With Multilineage Dysplasia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nk-92-acute-myeloid-leukemia-with-multilineage-dysplasia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →